Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: A randomized controlled crossover study

Intensive Care Medicine

Volumn 33, Issue 9, 2007, Pages 1571-1579

  Joannidis, Michael ^a   Kountchev, Jordan ^a   Rauchenzauner, Markus ^a   Schusterschitz, Nicola ^a   Ulmer, Hanno ^b   Mayr, Andreas ^b   Bellmann, Romuald ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anticoagulation; Costs; CVVH; Enoxaparin; Filter life span; Low molecular weight heparin; Renal replacement therapy; Safety; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTICOAGULATION; APACHE; ARTICLE; BLEEDING; BLOOD FLOW VELOCITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS VENO VENOUS HEMOFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EVALUATION; FEMALE; HEMOFILTRATION; HUMAN; INTENSIVE CARE UNIT; LIFESPAN; LIQUID; MALE; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; APACHE; COST-BENEFIT ANALYSIS; CROSS-OVER STUDIES; ENOXAPARIN; FEMALE; HEMOFILTRATION; HEPARIN; HUMANS; INTENSIVE CARE UNITS; KIDNEY FAILURE; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 34548168092     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0719-7     Document Type: Article

References (40)

1. Ricci Z, Ronco C, D'Amico G, Felice R de, Rossi S, Bolgan I, Bonello M, Zamperetti N, Petras D, Salvatori G, Dan M, Piccinni P (2006) Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 21:690-696
2. Oudemans-van Straaten HM, Wester JP, Pont AC de, Schetz MR (2006) Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 32:188-202
3. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S-94S
4. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractioned heparin. N Engl J Med 332:1330-1335
5. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR (1990) A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractioned heparin. Nephrol Dial Transplant 5:135-140
6. Schrader J, Valentin R, Tonnis HJ, Hildebrand U, Stibbe W, Armstrong VW, Kandt M, Kostering H, Quellhorst E (1985) Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int 28:823-829
7. Bambauer R, Rucker S, Weber U, Kohler M (1990) Comparison of low molecular weight heparin and standard heparin in hemodialysis. ASAIO Trans 36:M646-M649
8. Deuber HJ, Schulz W (1991) Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 40:496-500
9. Elisaf MS, Germanos NP, Bairaktari HT, Pappas MB, Koulouridis EI, Siamopoulos KC (1997) Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 17:153-157
10. Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM (1993) Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. Artif Organs 17:717-720
11. Pont AC de, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF (2000) Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Crit Care Med 28:421-425
12. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD (1999) A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractioned heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224-2228
13. Joannidis M, Kountchev J, Grote A, Bellmann R, Mayr AJ, Wiedermann CJ (2004) Unfractioned versus low-molecular-weight heparin(enoxaparin) for anticoagulation in CVVH. Intensive Care Med 30:S155 (Abstract)
14. Lemaire F, Bion J, Blanco J, Damas P, Druml C, Falke K, Kesecioglu J, Larsson A, Mancebo J, Matamis D, Pesenti A, Pimentel J, Ranieri M (2005) The European Union Directive on Clinical Research: present status of implementation in EU member states' legislations with regard to the incompetent patient. Intensive Care Med 31:476-479
15. Aguilar D, Goldhaber SZ (1999) Clinical uses of low-molecular-weight heparins. Chest 115:1418-1423
16. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M (1989) The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 62:940-944
17. Ireland H, Lane DA, Curtis JR (1984) Objective assessment of heparin requirements for hemodialysis in humans. J Lab Clin Med 103:643-652
18. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:311S-337S
19. Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W (2002) Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 105:201-204
20. Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dunser MW (2005) Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 9:R541-R548
21. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC (1996) Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 7:145-150
22. Martin PY, Chevrolet JC, Suter P, Favre H (1994) Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 24:806-812
23. Kozek-Langenecker SA, Kettner SC, Oismueller C, Gonano C, Speiser W, Zimpfer M (1998) Anticoagulation with prostaglandin E1 and unfractioned heparin during continuous venovenous hemofiltration. Crit Care Med 26:1208-1212
24. Tan HK, Baldwin I, Bellomo R (2000) Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 26:1652-1657
25. Vargas HO, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C (2001) Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 27:673-679
26. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673-684
27. Brophy DF, Wazny LD, Gehr TW, Comstock TJ, Venitz J (2001) The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 21:169-174
28. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A (2003) Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 43:586-590
29. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753-759
30. Nagge J, Crowther M, Hirsh J (2002) Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162:2605-2609
31. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF (2000) Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20:771-775
32. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E, Leger P, Fontan B, Massip P, Montastruc JL (2003) Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Safety 26:197-207
33. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA (2004) Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractioned heparin vs. enoxaparin. Chest 125:856-863
34. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM (2003) Safety and efficacy of unfractioned heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146:33-41
35. Dodds A, Nicholls M (1983) Haematological aspects of renal disease. Anaesth Intensive Care 11:361-368
36. Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A (2001) Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int 59:1510-1519
37. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractioned and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710-2715
38. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30
39. Bouman CS, Oudemans-van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J (2002) Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 30:2205-2211
40. DuBose TD Jr, Warnock DG, Mehta RL, Bonventre JV, Hammerman MR, Molitoris BA, Paller MS, Siegel NJ, Scherbenske J, Striker GE (1997) Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am J Kidney Dis 29:793-799